肿瘤细胞治疗研究
MODALITY HUB
FOR TREATMENT
按「中国试验优先 → 正在招募 → 更新更近」排序。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性，以登记原文和主治医生判断为准。
FOR RESEARCH
Secondary peripheral T-cell lymphoma in a patient with DLBCL harboring BLM mutation following CD19/CD22 bispecific CAR-T cell therapy.
我们描述了一例继发性外周 T 细胞淋巴瘤（PTCL），其来源于一名携带致病性胚系 BLM p.L107Ffs*36 变异的复发或难治性 B 细胞淋巴瘤患者输注的 CD19/CD22-4-1BB-CD3-lenti 双特异性嵌合抗原受体（CAR）-T 细胞。
Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma.
双特异性 CD19/20 CAR-T 疗法产生了持久的临床活性，且毒性可控。
Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial.
约30%对axicabtagene ciloleucel（axi-cel；靶向CD19的嵌合抗原受体（CAR）T细胞疗法）有应答的复发或难治性大B细胞淋巴瘤（LBCL）患者会出现CD19阴性复发。
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial.
非霍奇金淋巴瘤（NHL）是血液系统常见的恶性肿瘤，传统治疗对复发/难治性NHL（R/R NHL）患者疗效有限，尤其是弥漫大B细胞淋巴瘤（DLBCL）患者。
Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma.
中位年龄为 59 岁（范围 27-83），46/52 例为 III/IV 期疾病，中位随访时间为 21.6 个月。
Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.
识别 CD19 的 CAR T 细胞可有效治疗复发/难治性 B-ALL 和 DLBCL。
Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells.
LV20.19 CAR-T 的初步试验表明，R/R B 细胞恶性肿瘤患者的长期结果良好。
Unique loop-structured CD19/CD22 bispecific CAR-T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma: an observational s
CD19/CD22 BS Loop CAR-T 细胞疗法表现出强效的抗淋巴瘤活性，同时解决了设计对两种抗原具有同等效力的 CAR-T 细胞所面临的挑战。
Detection of HIV RNA after CAR-T Cell Therapy in A Relapsed/refractory Diffuse Large B-cell Lymphoma Patient: Possibility of False Positivity and Clin
使用慢病毒载体的CAR-T细胞治疗可能导致HIV RNA假阳性检测，使得区分真感染与载体相关信号具有挑战性。
Circulating tumor DNA determining hyperprogressive disease after CAR-T therapy alarms in DLBCL: a case report and literature review.
CAR-T 细胞疗法（CAR-T）因其良好疗效，已被广泛应用于复发/难治性（R/R）弥漫大 B 细胞淋巴瘤（DLBCL）的临床实践。
MEMBER ACCOUNT
登录成功会直接打开下一页。
